BrainStorm Cell Therapeutics Inc. is a company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The technology allows for the differentiation of bone marrow-derived stem cells into functional neurons and astrocytes.

BrainStorm Cell Therapeutics is currently focusing its technology on two diseases – Parkinson’s and ALS, which is also known as Lou Gehrig’s disease. The company announced today that it has entered into an agreement with Protein Production Services Ltd., a leading manufacturing contractor, in order to start “good manufacturing practice” production of its stem cell therapeutic product.

The clinical-grade product will be used in a pre-clinical safety trial for the company’s innovative therapy for Lou Gehrig’s disease. BrainStorm’s proprietary adult stem cell technologies have already been successfully tested on various animal models of neurodegenerative diseases. Neuro-protective and neuro-regenerative applications of the technology have been published in more than a dozen peer-reviewed scientific journals.

Rami Efrati, CEO of BrainStorm Cell Therapeutics, said, “We are very excited that we are moving into this phase of product development with a highly-experienced contractor that will enable us to move rapidly ahead with the final stage of our ALS pre-clinical program.”

Mr. Efrati added, “As we announced on August 24 after securing new funding, BrainStorm now has both the financing and the production capabilities to achieve our goal of reaching human clinical studies in the coming year.”